Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists

Journal of the American Society of Nephrology

Volumn 19, Issue 9, 2008, Pages 1721-1731

  Perucca, Julie ^a,b   Bichet, Daniel G ^c   Bardoux, Pascale ^a   Bouby, Nadine ^a,b   Bankir, Lise ^a,b  

^a INSERM   (France)

^b CENTRE DE RECHERCHE DES CORDELIERS   (France)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; DESMOPRESSIN; FUROSEMIDE; RELCOVAPTAN; SATAVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V2 RECEPTOR; ARGIPRESSIN[1 DEAMINO]; DIURETIC AGENT; MORPHOLINE DERIVATIVE; SODIUM; SPIRO COMPOUND; VASOPRESSIN RECEPTOR;

ANIMAL EXPERIMENT; ANTIDIURESIS; ARTICLE; DOSE RESPONSE; KIDNEY MEDULLA; MALE; MICTURITION; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SODIUM EXCRETION; SODIUM RETENTION; URINE FLOW RATE; WISTAR RAT; ANIMAL; DRUG ANTAGONISM; DRUG POTENTIATION; URINE;

ANIMALS; ARGININE VASOPRESSIN; DEAMINO ARGININE VASOPRESSIN; DIURETICS; DOSE-RESPONSE RELATIONSHIP, DRUG; FUROSEMIDE; MALE; MORPHOLINES; RATS; RATS, WISTAR; RECEPTORS, VASOPRESSIN; SODIUM; SPIRO COMPOUNDS; URINE;

EID: 54749134723     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2008010021     Document Type: Article

References (66)

1. Schafer JA: Abnormal regulation of ENaC: Syndromes of salt retention and salt wasting by the collecting duct. Am J Physiol Renal Physiol 283: F221-F235, 2002
2. Leaf A, Bartter FC, Santos RF, Wrong O: Evidence in man that urinary electrolyte loss induced by pitressin is a function of water retention. J Clin Invest 32: 868-878, 1953
3. Humphreys MH, Friedler RM, Earley LE: Natriuresis produced by vasopressin or hemorrhage during water diuresis in the dog. Am J Physiol 219: 658-665, 1970
4. Buckalew VM, Dimond KA: Effect of vasopressin on sodium excretion and plasma antinatriferic activity in the dog. Am J Physiol 231: 28-33, 1976
5. Balment RJ, Brimble MJ, Forsling ML, Musabayane CT: Natriuretic response of the rat to plasma concentrations of arginine vasopressin within the physiological range. J Physiol 352: 517-526, 1984
6. Park RG, Congiu M, Denton DA, McKinley MJ: Natriuresis induced by arginine vasopressin infusion in sheep. Am J Physiol 249: F799-F805, 1985
7. Forsling ML, Judah JM, Windle RJ: The effect of vasopressin and oxytocin on glomerular filtration rate in the conscious rat: Contribution to the natriuretic response. J Endocrinol 141: 59-67, 1994
8. Walter SJ, Tennakoon V, McClune JA, Shirley DG: Role of volume status in vasopressin-induced natriuresis: Studies in Brattleboro rats. J Endocrinol 151: 49-54, 1996
9. Kompanowska-Jezierska E, Emmeluth C, Grove L, Christensen P, Sadowski J, Bie P: Mechanism of vasopressin natriuresis in the dog: Role of vasopressin receptors and prostaglandins. Am J Physiol 274: R1619-R1625, 1998
10. Verbalis JG: Vasopressin V2 receptor antagonists. J Mol Endocrinol 29: 1-9, 2002
11. Lemmens-Gruber R, Kamyar M: Vasopressin antagonists. Cell Mol Life Sci 63: 1766-1779, 2006
12. Torres VE: Vasopressin antagonists in polycystic kidney disease. Kidney Int 68: 2405-2418, 2005
13. Bankir L, Perucca J, Weinberger MH: Ethnic differences in urine concentration: Possible relationship to blood pressure. Clin J Am Soc Nephrol 2: 304-312, 2007
14. Ando Y, Asano Y: Functional evidence for an apical V1 receptor in rabbit cortical collecting duct. Am J Physiol 264: F467-F471, 1993
15. 2+ response to luminal vasopressin in cortical collecting tubule principal cells. Kidney Int 45: 811-816, 1994
16. Robertson GL: The regulation of vasopressin function in health and disease. Recent Progr Horm Res 33: 333-385, 1977
17. Bankir L: Antidiuretic action of vasopressin: Quantitative aspects and interaction between V1a and V2 receptor-mediated effects. Cardiovasc Res 51: 372-390, 2001
18. Serradeil-Le Gal C, Derick S, Brossard G, Manning M, Simiand J, Gaillard R, Griebel G, Guillon G: Functional and pharmacological characterization of the first specific agonist and antagonist for the V1b receptor in mammals. Stress 6: 199-206, 2003
19. Saito M, Tahara A, Sugimoto T: 1-Desamino-8-D-arginine vasopressin (DDAVP) as an agonist on V1b vasopressin receptor. Biochem Pharmacol 53: 1711-1717, 1997
20. Nicco C, Wittner M, DiStefano A, Jounier S, Bankir L, Bouby N: Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension 38: 1143-1149, 2001
21. Kim JK, Summer SN, Erickson AE, Schrier RW: Role of arginine vasopressin in medullary thick ascending limb on maximal urinary concentration. Am J Physiol 251: F266-F270, 1986
22. Huang DY, Pfaff I, Serradeil-Le Gal C, Vallon V: Acute renal response to the non-peptide vasopressin V2-receptor antagonist SR 121463B in anesthetized rats. Naunyn Schmiedebergs Arch Pharmacol 362: 201-207, 2000
23. Bankir L, Fernandes S, Bardoux P, Bouby N, Bichet DG: Vasopressin-V2 receptor stimulation reduces sodium excretion in healthy humans. J Am Soc Nephrol 16: 1920-1928, 2005
24. Lieberthal W, Vasilevsky ML, Valari R, Levinsky N: Interactions between ADH and prostaglandins in isolated erythrocyte-perfused rat kidney. Am J Physiol 252: F331-F337, 1987
25. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, Yamada Y, Tsujimae K, Aoyama M, Kotosai K, Ogawa H, Yamashita H, Kondo K, Tominaga M, Tsujimoto G, Mori T: OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 287: 860-867, 1998
26. Lacour C, Galindo G, Canals F, Segondy D, Cazaubon C, Serradeil-Le Gal C, Roccon A, Nisato D: Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats. Eur J Pharmacol 394: 131-138, 2000
27. Yamamura Y, Ogawa H, Yamashita H, Chihara T, Miyamoto H, Nakamura S, Onogawa T, Yamashita T, Hosokawa T, Mori T, et al.: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105: 787-791, 1992
28. Decaux G: Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985. J Lab Clin Med 138: 18-21, 2001
29. Guyader D, Patat A, Ellis-Grosse EJ, Orczyk GP: Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites. Hepatology 36: 1197-1205, 2002
30. Jimenez W, Gal CS, Ros J, Cano C, Cejudo P, Morales-Ruiz M, Arroyo V, Pascal M, Rivera F, Maffrand JP, Rodes J: Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats. J Pharmacol Exp Ther 295: 83-90, 2000
31. Anastasio P, Cirillo M, Spitali L, Frangiosa A, Pollastro RM, De Santo NG: Level of hydration and renal function in healthy humans. Kidney Int 60: 748-756, 2001
32. Choukroun G, Schmitt F, Martinez F, Drüeke TB, Bankir L: Low urine flow reduces the capacity to excrete a sodium load in humans. Am J Physiol 273: R1726-R1733, 1997
33. 2 antagonist OPC-21260 in hydropenic humans. Kidney Int 48: 220-226, 1995
34. Tsuboi Y, Ishikawa S, Fujisawa G, Okada K, Saito T: In vivo diuretic effect of a new non-peptide arginine vasopressin antagonist, OPC-31260, in conscious rats. J Endocrinol 143: 227-234, 1994
35. Field MJ, Stanton BA, Giebisch GH: Influence of ADH on renal potassium handling: A micropuncture and microperfusion study. Kidney Int 25: 502-511, 1984
36. Schafer JA, Troutman SL: Effect of ADH on rubidium transport in isolated perfused rat cortical collecting tubules. Am J Physiol 250: F1063-F1072, 1986
37. Malnic G, Berliner RW, Giebisch G: Flow dependence of K+ secretion in cortical distal tubules of the rat. Am J Physiol 256: F932-F941, 1989
38. Nadvornikova H, Schuck O: The influence of a single dose of vasopressin analogs on human renal potassium excretion. Int J Clin Pharmacol Ther Toxicol 20: 155-158, 1982
39. Manning PT, Schwartz D, Katsube NC, Holmberg SW, Needleman P: Vasopressin-stimulated release of atriopeptin: Endocrine antagonists in fluid homeostasis. Science 229: 395-397, 1985
40. Bonvalet JP, Pradelles P, Farman N: Segmental synthesis and actions of prostaglandins along the nephron. Am J Physiol 253: F377-F387, 1987
41. Chou SY, Porush JG, Faubert PF: Renal medullary circulation: Hormonal control. Kidney Int 37: 1-13, 1990
42. Schlondorff D: Renal prostaglandin synthesis: Sites of production and specific actions of prostaglandins. Am J Med 81: 1-11, 1986
43. Serradeil-Le Gal C, Raufaste D, Marty E, Garcia C, Maffrand JP, Le Fur G: Autoradiographic localization of vasopressin V1a receptors in the rat kidney using [3H]-SR 49059. Kidney Int 50: 499-505, 1996
44. Andersen LJ, Andersen JL, Schütten HJ, Warberg J, Bie P: Antidiuretic effect of subnormal levels of arginine vasopressin in normal humans. Am J Physiol 259: R53-R60, 1990
45. Bankir L, Pouzet B, Choukroun G, Bouby N, Schmitt F, Mallie JP: To concentrate the urine or to excrete sodium: Two sometimes contradictory requirements [in French]. Nephrologie 19: 203-209, 1998
46. Thibonnier M, Kilani A, Rahman M, Pilumeli DiBlasi T, Warner K, Smith MC, Leenhardt AF, Brouard R: Effects of the nonpeptide V1 vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension 34: 1293-1300, 1999
47. Fernandes S, Bruneval P, Hagege A, Heudes D, Ghostine S, Bouby N: Chronic V2 vasopressin receptor stimulation increases basal blood pressure and exacerbates deoxycorticosterone acetate-salt hypertension. Endocrinol 143: 2759-2766, 2002
48. Montani J, Wang J, Tempini A, Yang Z, Van Vliet B: Chronic V2-vasopressin receptor stimulation at both moderate and high doses induces sustained hypertension in rats [Abstract]. FASEB J 15: A133, 2001
49. Yagil C, Ben-Ishay D, Yagil Y: Disparate expression of the AVP gene in Sabra hypertension-prone and hypertension-resistant rats. Am J Physiol 271: F806-F813, 1996
50. Bankir L, Bardoux P, Mayaudon H, Dupuy O, Bauduceau B: Impaired urinary flow rate during the day: A new factor possibly involved in hypertension and in the lack of nocturnal dipping [in French]. Arch Mal Coeur Vaiss 95: 751-754, 2002
51. Izumi Y, Nakayama Y, Mori T, Miyazaki H, Inoue H, Kohda Y, Inoue T, Nonoguchi H, Tomita K: Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway. Am J Physiol Renal Physiol 292: F1418-F1426, 2007
52. Loichot C, Cazaubon C, Grima M, De Jong W, Nisato D, Imbs JL, Barthelmebs M: Vasopressin does not effect hypertension caused by long-term nitric oxide inhibition. Hypertension 35: 602-608, 2000
53. Mechaly I, Krosniak M, Azay J, Cassanas G, Roque C, Cahard D, Serrano JJ, Cros G: Interactive computerized microscopy as a tool for quantifying vascular remodelling effects of diabetes and V1a receptor antagonist SR 49059 on rat mesenteric arterial bed. J Pharmacol Toxicol Methods 41: 59-67, 1999
54. Promeneur D, Bankir L, Hu MC, Trinh-Trang-Tan MM: Renal tubular and vascular urea transporters: Influence of antidiuretic hormone on mRNA expression in Brattleboro rats. J Am Soc Nephrol 9: 1359-1366, 1998
55. Berl T, Raz A, Wald H, Horowitz J, Czaczkes W: Prostaglandin synthesis inhibition and the action of vasopressin: studies in man and rat. Am J Physiol 232: F529-F537, 1977
56. Breyer MD, Ando Y: Hormonal signaling and regulation of salt and water transport in the collecting duct. Annu Rev Physiol 56: 711-739, 1994
57. Bouby N, Hassler C, Bankir L: Contribution of vasopressin to progression of chronic renal failure: Study in Brattleboro rats infused with AVP or dDAVP. Life Sci 65: 991-1004, 1999
58. Nonoguchi H, Takayama M, Owada A, Ujiie K, Yamada T, Nakashima O, Sakuma Y, Koike J, Terada Y, Marumo F, Tomita K: Role of urinary arginine vasopressin in the sodium excretion in patients with chronic renal failure. Am J Med Sci 312: 195-201, 1996
59. Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, Adachi T, Tanaka T, Kuwaki T, Mori T, Takeo S, Okamura H, Tsujimoto G: V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A 103: 7807-7812, 2006
60. Luft FC: Vasopressin, urine concentration, and hypertension: A new perspective on an old story. Clin J Am Soc Nephrol 2: 196-197, 2007
61. Richardson DW, Robinson AG: Desmopressin. Ann Intern Med 103: 228-239, 1985
62. Serradeil-Le-Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le-Fur G: Characterization of SR 121463A, a highly potent and selective orally active vasopressin V2 receptor antagonist. J Clin Invest 98: 2729-2738, 1996
63. Serradeil-Le Gal C: An overview of SR121463, a selective non-peptide vasopressin V(2) receptor antagonist. Cardiovasc Drug Rev 19: 201-214, 2001
64. Serradeil-Le Gal C, Wagnon J, Garcia C, Lacour C, Guiraudou P, Christophe B, Villanova G, Nisato D, Maffrand JP, Le Fur G, et al.: Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors. J Clin Invest 92: 224-231, 1993
65. Bichet DG, Arthus MF, Barjon JN, Lonergan M, Kortas C: Human platelet fraction arginine-vasopressin: Potential physiological role. J Clin Invest 79: 881-887, 1987
66. West ML, Bendz O, Chen CB, Singer GG, Richardson RM, Sonnenberg H, Halperin ML: Development of a test to evaluate the transtubular potassium concentration gradient in the cortical collecting duct in vivo. Miner Electrolyte Metab 12: 226-233, 1986